Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Scilipoti

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Current Opinion in Urology|May 2, 2026
Current applications of augmented reality in urology: clinical practice, training, and future directions: an EAU endourology and YAU opinionPietro Scilipoti, Olivier Traxer, Frédéric Panthier
Cell Reports. Medicine|December 18, 2024
Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinomaPietro Scilipoti, Marco Moschini, Alberto Briganti
Current Opinion in Urology|July 15, 2025
Intravesical chemotherapy combination treatments for BCG-unresponsive nonmuscle invasive bladder cancerPaolo Zaurito, Pietro Scilipoti, Francesco Montorsi, et al.
European Urology|January 20, 2026
Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease SettingsRenate Pichler, José Daniel Subiela, Pietro Scilipoti, et al.
Journal of the National Cancer Institute|January 17, 2025
Incidence and prognostic implications of prostate-specific antigen persistence and relapse after radical prostatectomy: population-based studyPietro Scilipoti, Hans Garmo, Rolf Gedeborg, et al.
European Urology Open Science|June 1, 2026
Estimation and Prognostic Role of Prostate-specific Antigen (PSA) Doubling Time After Radical ProstatectomyPietro Scilipoti, Max Callenmark, Hans Garmo, et al.
JNCI Cancer Spectrum|February 6, 2025
Functional outcomes after primary vs delayed robot-assisted radical prostatectomy following active surveillanceChristian Corsini, Pietro Scilipoti, Andri Wilberg Orrason, et al.
Scandinavian Journal of Urology|February 27, 2025
Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based studyAndri Wilberg Orrason, Pietro Scilipoti, Hans Garmo, et al.
Scandinavian Journal of Urology|May 13, 2024
Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based studyPietro Scilipoti, Fredrik Liedberg, Hans Garmo, et al.
European Urology|May 15, 2025
Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical CystectomyJosé Daniel Subiela, Pietro Scilipoti, Roberto Contieri, et al.
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Current Opinion in Urology|May 2, 2026
Current applications of augmented reality in urology: clinical practice, training, and future directions: an EAU endourology and YAU opinionPietro Scilipoti, Olivier Traxer, Frédéric Panthier
Cell Reports. Medicine|December 18, 2024
Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinomaPietro Scilipoti, Marco Moschini, Alberto Briganti
Current Opinion in Urology|July 15, 2025
Intravesical chemotherapy combination treatments for BCG-unresponsive nonmuscle invasive bladder cancerPaolo Zaurito, Pietro Scilipoti, Francesco Montorsi, et al.
European Urology|January 20, 2026
Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease SettingsRenate Pichler, José Daniel Subiela, Pietro Scilipoti, et al.
Journal of the National Cancer Institute|January 17, 2025
Incidence and prognostic implications of prostate-specific antigen persistence and relapse after radical prostatectomy: population-based studyPietro Scilipoti, Hans Garmo, Rolf Gedeborg, et al.
European Urology Open Science|June 1, 2026
Estimation and Prognostic Role of Prostate-specific Antigen (PSA) Doubling Time After Radical ProstatectomyPietro Scilipoti, Max Callenmark, Hans Garmo, et al.
JNCI Cancer Spectrum|February 6, 2025
Functional outcomes after primary vs delayed robot-assisted radical prostatectomy following active surveillanceChristian Corsini, Pietro Scilipoti, Andri Wilberg Orrason, et al.
Scandinavian Journal of Urology|February 27, 2025
Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based studyAndri Wilberg Orrason, Pietro Scilipoti, Hans Garmo, et al.
Scandinavian Journal of Urology|May 13, 2024
Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based studyPietro Scilipoti, Fredrik Liedberg, Hans Garmo, et al.
European Urology|May 15, 2025
Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical CystectomyJosé Daniel Subiela, Pietro Scilipoti, Roberto Contieri, et al.
Pageof 10